The Gut Microbiome in Aging and Ovarian Cancer
Gena M. Dominique,
Catherine Hammond,
M. Sharon Stack,
Gena M. Dominique
Department of Chemistry and Biochemistry, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, Indiana, USA
Contribution: Conceptualization (equal), Funding acquisition (equal), Investigation (equal), Project administration (equal), Visualization (lead), Writing - original draft (lead), Writing - review & editing (lead)
Search for more papers by this authorCatherine Hammond
Department of Biology, University of Notre Dame, Notre Dame, Indiana, USA
Contribution: Investigation (supporting), Writing - original draft (supporting), Writing - review & editing (supporting)
Search for more papers by this authorCorresponding Author
M. Sharon Stack
Department of Chemistry and Biochemistry, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, Indiana, USA
Correspondence: M. Sharon Stack ([email protected])
Contribution: Conceptualization (equal), Funding acquisition (lead), Writing - review & editing (equal)
Search for more papers by this authorGena M. Dominique,
Catherine Hammond,
M. Sharon Stack,
Gena M. Dominique
Department of Chemistry and Biochemistry, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, Indiana, USA
Contribution: Conceptualization (equal), Funding acquisition (equal), Investigation (equal), Project administration (equal), Visualization (lead), Writing - original draft (lead), Writing - review & editing (lead)
Search for more papers by this authorCatherine Hammond
Department of Biology, University of Notre Dame, Notre Dame, Indiana, USA
Contribution: Investigation (supporting), Writing - original draft (supporting), Writing - review & editing (supporting)
Search for more papers by this authorCorresponding Author
M. Sharon Stack
Department of Chemistry and Biochemistry, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, Indiana, USA
Correspondence: M. Sharon Stack ([email protected])
Contribution: Conceptualization (equal), Funding acquisition (lead), Writing - review & editing (equal)
Search for more papers by this authorFirst published: 20 June 2024
Funding: This research was funded by National Institutes of Health/National Cancer Institute (Grants RO1CA109545 [M.S.S.] and UO1CA236979 [M.S.S.]), the Samuel Waxman Cancer Research Foundation (M.S.S.), and the Dolores Zohrab Liebmann Fund (G.M.D.).
ABSTRACT
The gut microbiome changes with age and affects regions beyond the gut, including the ovarian cancer tumor microenvironment. In this review summarizing the literature on the gut microbiome in ovarian cancer and in aging, we note trends in the microbiota composition common to both phenomena and trends that are distinctly opposite. Both ovarian cancer and aging are characterized by an increase in proinflammatory bacterial species, particularly those belonging to phylum Proteobacteria and genus Escherichia, and a decrease in short-chain fatty acid producers, particularly those in Clostridium cluster XIVa (family Lachnospiraceae) and the Actinobacteria genus Bifidobacterium. However, although beneficial bacteria from family Porphyromonadaceae and genus Akkermansia tend to increase with normal, healthy aging, these bacteria tend to decrease in ovarian cancer, similar to what is observed in obesity or unhealthy aging. We also note a lack in the current literature of research demonstrating causal relationships between the gut microbiome and ovarian cancer outcomes and research on the gut microbiome in ovarian cancer in the context of aging, both of which could lead to improvements to ovarian cancer diagnosis and treatment.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The authors have nothing to report.
References
- 1E. M. Park, M. Chelvanambi, N. Bhutiani, G. Kroemer, L. Zitvogel, and J. A. Wargo, “Targeting the Gut and Tumor Microbiota in Cancer,” Nature Medicine 28, no. 4 (2022): 690–703, https://doi.org/10.1038/s41591-022-01779-2.
- 2V. Gopalakrishnan, B. A. Helmink, C. N. Spencer, A. Reuben, and J. A. Wargo, “The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy,” Cancer Cell 33, no. 4 (2018): 570–580, https://doi.org/10.1016/j.ccell.2018.03.015.
- 3G. Berg, D. Rybakova, D. Fischer, et al., “Microbiome Definition Re-Visited: Old Concepts and New Challenges,” Microbiome 8, no. 1 (2020): 103, https://doi.org/10.1186/s40168-020-00875-0.
- 4E. Lengyel, “Ovarian Cancer Development and Metastasis,” American Journal of Pathology 177, no. 3 (2010): 1053–1064, https://doi.org/10.2353/ajpath.2010.100105.
- 5Y. Klymenko, O. Kim, E. Loughran, et al., “Cadherin Composition and Multicellular Aggregate Invasion in Organotypic Models of Epithelial Ovarian Cancer Intraperitoneal Metastasis,” Oncogene 36, no. 42 (2017): 5840–5851, https://doi.org/10.1038/onc.2017.171.
- 6R. A. Davidowitz, L. M. Selfors, M. P. Iwanicki, et al., “Mesenchymal Gene Program–Expressing Ovarian Cancer Spheroids Exhibit Enhanced Mesothelial Clearance,” Journal of Clinical Investigation 124, no. 6 (2014): 2611–2625, https://doi.org/10.1172/JCI69815.
- 7M. Asem, A. Young, C. Oyama, et al., “Ascites-Induced Compression Alters the Peritoneal Microenvironment and Promotes Metastatic Success in Ovarian Cancer,” Scientific Reports 10, no. 1 (2020): 11913, https://doi.org/10.1038/s41598-020-68639-2.
- 8R. L. Siegel, K. D. Miller, N. S. Wagle, and A. Jemal, “Cancer Statistics, 2023,” CA: A Cancer Journal for Clinicians 73, no. 1 (2023): 17–48, https://doi.org/10.3322/caac.21763.
- 9B. T. Hennessy, R. L. Coleman, and M. Markman, “Ovarian Cancer,” Lancet 374, no. 9698 (2009): 1371–1382, https://doi.org/10.1016/S0140-6736(09)61338-6.
- 10M. R. Mirza, R. L. Coleman, A. González-Martín, et al., “The Forefront of Ovarian Cancer Therapy: Update on PARP Inhibitors,” Annals of Oncology 31, no. 9 (2020): 1148–1159, https://doi.org/10.1016/j.annonc.2020.06.004.
- 11S. Garzon, A. S. Laganà, J. Casarin, et al., “Secondary and Tertiary Ovarian Cancer Recurrence: What Is the Best Management?” Gland Surgery 9, no. 4 (Published online 2020): 1118–1129, https://gs.amegroups.org/article/view/43271.
- 12E. I. Harper, E. F. Sheedy, and M. S. Stack, “With Great Age Comes Great Metastatic Ability: Ovarian Cancer and the Appeal of the Aging Peritoneal Microenvironment,” Cancers (Basel) 10, no. 7 (2018): 230, https://doi.org/10.3390/cancers10070230.
- 13N. Howlader, A. Noone, M. Krapcho, et al., “SEER Cancer Statistics Review, 1975–2017,” National Cancer Institute. Published online 2020. https://seer.cancer.gov/csr/1975_2017/.
- 14V. D. Badal, E. D. Vaccariello, E. R. Murray, et al., “The Gut Microbiome, Aging, and Longevity: A Systematic Review,” Nutrients 12, no. 12 (2020): 3759, https://doi.org/10.3390/nu12123759.
- 15Z. Ling, X. Liu, Y. Cheng, X. Yan, and S. Wu, “Gut Microbiota and Aging,” Critical Reviews in Food Science and Nutrition 62, no. 13 (2022): 3509–3534, https://doi.org/10.1080/10408398.2020.1867054.
- 16Z. Wang, X. Qin, D. Hu, et al., “Akkermansia Supplementation Reverses the Tumor-Promoting Effect of the Fecal Microbiota Transplantation in Ovarian Cancer,” Cell Reports 41, no. 13 (2022): 111890, https://doi.org/10.1016/j.celrep.2022.111890.
- 17X. Hu, X. Xu, X. Zeng, et al., “Gut Microbiota Dysbiosis Promotes the Development of Epithelial Ovarian Cancer via Regulating Hedgehog Signaling Pathway,” Gut Microbes 15, no. 1 (2023): 2221093, https://doi.org/10.1080/19490976.2023.2221093.
- 18F. D'Amico, A. M. Perrone, S. Rampelli, et al., “Gut Microbiota Dynamics during Chemotherapy in Epithelial Ovarian Cancer Patients Are Related to Therapeutic Outcome,” Cancers (Basel) 13, no. 16 (2021): 3999, https://doi.org/10.3390/cancers13163999.
- 19A. E. Asangba, J. Chen, K. M. Goergen, et al., “Diagnostic and Prognostic Potential of the Microbiome in Ovarian Cancer Treatment Response,” Scientific Reports 13, no. 1 (2023): 730, https://doi.org/10.1038/s41598-023-27555-x.
- 20D. Jacobson, K. Moore, C. Gunderson, et al., “Shifts in Gut and Vaginal Microbiomes Are Associated With Cancer Recurrence Time in Women With Ovarian Cancer,” PeerJ 9, (2021): e11574, https://doi.org/10.7717/peerj.11574.
- 21L. M. Chambers, M. Kuznicki, M. Yao, et al., “Impact of Antibiotic Treatment During Platinum Chemotherapy on Survival and Recurrence in Women With Advanced Epithelial Ovarian Cancer,” Gynecologic Oncology 159, no. 3 (2020): 699–705, https://doi.org/10.1016/j.ygyno.2020.09.010.
- 22L. M. Chambers, E. L. Esakov Rhoades, R. Bharti, et al., “Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer,” Cancer Research 82, no. 24 (2022): 4654–4669, https://doi.org/10.1158/0008-5472.CAN-22-0455.
- 23X. Zhan, Q. Zuo, G. Huang, et al., “Tripterygium Glycosides Sensitizes Cisplatin Chemotherapeutic Potency by Modulating Gut Microbiota in Epithelial Ovarian Cancer,” Frontiers in Cellular and Infection Microbiology 13, (2023): 1236272, https://www.frontiersin.org/articles/10.3389/fcimb.2023.1236272.
- 24J. Tong, X. Zhang, Y. Fan, et al., “Changes of Intestinal Microbiota in Ovarian Cancer Patients Treated with Surgery and Chemotherapy,” Cancer Management and Research 12, no. null (2020): 8125–8135, https://doi.org/10.2147/CMAR.S265205.
- 25A. Perales-Puchalt, J. Perez-Sanz, K. K. Payne, et al., “Frontline Science: Microbiota Reconstitution Restores Intestinal Integrity After Cisplatin Therapy,” Journal of Leukocyte Biology 103, no. 5 (2018): 799–805, https://doi.org/10.1002/JLB.5HI1117-446RR.
- 26A. Vaiserman, M. Romanenko, L. Piven, et al., “Differences in the Gut Firmicutes to Bacteroidetes Ratio Across Age Groups in Healthy Ukrainian Population,” BMC Microbiology 20, no. 1 (2020): 221, https://doi.org/10.1186/s12866-020-01903-7.
- 27M. J. Claesson, S. Cusack, O. O'Sullivan, et al., “Composition, Variability, and Temporal Stability of the Intestinal Microbiota of the Elderly,” Proceedings of the National Academy of Sciences of the United States of America 108, no. S1 (2011): 4586–4591, https://doi.org/10.1073/pnas.1000097107.
- 28E. Biagi, L. Nylund, M. Candela, et al., “Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians,” PLoS ONE 5, no. 5 (2010): e10667, https://doi.org/10.1371/journal.pone.0010667.
- 29T. Odamaki, K. Kato, H. Sugahara, et al., “Age-Related Changes in Gut Microbiota Composition From Newborn to Centenarian: A Cross-Sectional Study,” BMC Microbiology 16, no. 1 (2016): 90, https://doi.org/10.1186/s12866-016-0708-5.
- 30T. Yatsunenko, F. E. Rey, M. J. Manary, et al., “Human Gut Microbiome Viewed Across Age and Geography,” Nature 486, no. 7402 (2012): 222–227, https://doi.org/10.1038/nature11053.
- 31T. Wilmanski, C. Diener, N. Rappaport, et al., “Gut Microbiome Pattern Reflects Healthy Ageing and Predicts Survival in Humans,” Nature Metabolism 3, no. 2 (2021): 274–286, https://doi.org/10.1038/s42255-021-00348-0.
- 32F. Asnicar, S. E. Berry, A. M. Valdes, et al., “Microbiome Connections with Host Metabolism and Habitual Diet From 1,098 Deeply Phenotyped Individuals,” Nature Medicine 27, no. 2 (2021): 321–332, https://doi.org/10.1038/s41591-020-01183-8.
- 33M. J. Claesson, I. B. Jeffery, S. Conde, et al., “Gut Microbiota Composition Correlates with Diet and Health in the Elderly,” Nature 488, no. 7410 (2012): 178–184, https://doi.org/10.1038/nature11319.
- 34Y. Ye, Y. Gao, Y. Fang, L. Xu, and F. He, “Anticancer Effect of Puerarin on Ovarian Cancer Progression Contributes to the Tumor Suppressor Gene Expression and Gut Microbiota Modulation,” Journal of Immunology Research 2022, (2022): 4472509, https://doi.org/10.1155/2022/4472509.
- 35F. Borella, A. R. Carosso, S. Cosma, et al., “Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions,” ACS Infect Dis 7, no. 5 (2021): 987–1009, https://doi.org/10.1021/acsinfecdis.0c00839.
- 36H. Cheng, Z. Wang, L. Cui, et al., “Opportunities and Challenges of the Human Microbiome in Ovarian Cancer,” Frontiers in Oncology 10, (2020): 163, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00163.
- 37M. Han, N. Wang, W. Han, M. Ban, T. Sun, and J. Xu, “Gut Microbes in Gynecologic Cancers: Causes or Biomarkers and Therapeutic Potential,” Frontiers in Oncology 12, (2022): 902695, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.902695.
- 38J. Yang, Q. Tan, Q. Fu, et al., “Gastrointestinal Microbiome and Breast Cancer: Correlations, Mechanisms and Potential Clinical Implications,” Breast Cancer (Tokyo, Japan) 24, no. 2 (2017): 220–228, https://doi.org/10.1007/s12282-016-0734-z.
- 39N. Alizadehmohajer, S. Shojaeifar, R. Nedaeinia, et al., “Association Between the Microbiota and Women's Cancers – Cause or Consequences?” Biomedicine and Pharmacotherapy 127, (2020): 110203, https://doi.org/10.1016/j.biopha.2020.110203.
- 40S. Lilja, C. Stoll, U. Krammer, et al., “Five Days Periodic Fasting Elevates Levels of Longevity Related Christensenella and Sirtuin Expression in Humans,” International Journal of Molecular Sciences 22, no. 5 (2021): 2331, https://doi.org/10.3390/ijms22052331.
- 41W. Fusco, M. B. Lorenzo, M. Cintoni, et al., “Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota,” Nutrients 15, no. 9 (2023): 2211, https://doi.org/10.3390/nu15092211.
- 42A. J. La Reau, J. P. Meier-Kolthoff, and G. Suen, “Sequence-Based Analysis of the Genus Ruminococcus Resolves Its Phylogeny and Reveals Strong Host Association,” Microbial Genomics 2, no. 12 (2016): e000099, https://doi.org/10.1099/mgen.0.000099.
- 43F. Thomas, J.-H. Hehemann, E. Rebuffet, M. Czjzek, and G. Michel, “Environmental and Gut Bacteroidetes: The Food Connection,” Frontiers in Microbiology 2, (2011): 93, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2011.00093.
- 44T. Tavella, S. Rampelli, G. Guidarelli, et al., “Elevated Gut Microbiome Abundance of Christensenellaceae, Porphyromonadaceae and Rikenellaceae Is Associated with Reduced Visceral Adipose Tissue and Healthier Metabolic Profile in Italian Elderly,” Gut Microbes 13, no. 1 (2021): 1880221, https://doi.org/10.1080/19490976.2021.1880221.
- 45V. Palmas, S. Pisanu, V. Madau, et al., “Gut Microbiota Markers Associated with Obesity and Overweight in Italian Adults,” Scientific Reports 11, no. 1 (2021): 5532, https://doi.org/10.1038/s41598-021-84928-w.
- 46J. M. Larsen, “The Immune Response to Prevotella Bacteria in Chronic Inflammatory Disease,” Immunology 151, no. 4 (2017): 363–374, https://doi.org/10.1111/imm.12760.
- 47M. Bilska, A. Pawłowska, E. Zakrzewska, et al., “Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy,” Journal of Oncology 2020, (2020): 8797683, https://doi.org/10.1155/2020/8797683.
- 48L. N. Dahal, “The Dichotomy of T Helper 17 Cells in Cancer,” Nature Reviews Immunology 17, no. 9 (2017): 592, https://doi.org/10.1038/nri.2017.93.
- 49G. Rizzatti, L. R. Lopetuso, G. Gibiino, C. Binda, and A. Gasbarrini, “Proteobacteria: A Common Factor in Human Diseases,” BioMed Research International 2017, (2017): 9351507, https://doi.org/10.1155/2017/9351507.
- 50N. Pflug, S. Kluth, J. J. Vehreschild, et al., “Efficacy of Antineoplastic Treatment Is Associated with the Use of Antibiotics That Modulate Intestinal Microbiota,” Oncoimmunology 5, no. 6 (2016): e1150399, https://doi.org/10.1080/2162402X.2016.1150399.
- 51N. Iida, A. Dzutsev, C. A. Stewart, et al., “Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment,” Science (80-) 342, no. 6161 (2013): 967–970, https://doi.org/10.1126/science.1240527.
- 52S. Xu, Z. Liu, M. Lv, Y. Chen, and Y. Liu, “Intestinal Dysbiosis Promotes Epithelial-Mesenchymal Transition by Activating Tumor-Associated Macrophages in Ovarian Cancer,” Pathogens and Disease 77, no. 2 (2019): ftz019, https://doi.org/10.1093/femspd/ftz019.
- 53L. Zhao, C. Xing, W. Sun, G. Hou, G. Yang, and L. Yuan, “Lactobacillus Supplementation Prevents Cisplatin-Induced Cardiotoxicity Possibly by Inflammation Inhibition,” Cancer Chemotherapy and Pharmacology 82, no. 6 (2018): 999–1008, https://doi.org/10.1007/s00280-018-3691-8.
- 54M. Sandri, S. Dal Monego, G. Conte, S. Sgorlon, and B. Stefanon, “Raw Meat Based Diet Influences Faecal Microbiome and End Products of Fermentation in Healthy Dogs,” BMC Veterinary Research 13, no. 1 (2017): 65, https://doi.org/10.1186/s12917-017-0981-z.
- 55Z. L. Tan, T. G. Nagaraja, and M. M. Chengappa, “Selective Enumeration of Fusobacterium necrophorum from the Bovine Rumen,” Applied and Environmental Microbiology 60, no. 4 (1994): 1387–1389.
- 56P. T. Koleva, J.-S. Kim, J. A. Scott, and A. L. Kozyrskyj, “Microbial Programming of Health and Disease Starts During Fetal Life,” Birth Defects Research Part C: Embryo Today: Reviews 105, no. 4 (2015): 265–277, https://doi.org/10.1002/bdrc.21117.
- 57L. Zhuang, H. Chen, S. Zhang, J. Zhuang, Q. Li, and Z. Feng, “Intestinal Microbiota in Early Life and Its Implications on Childhood Health,” Genomics, Proteomics and Bioinformatics 17, no. 1 (2019): 13–25, https://doi.org/10.1016/j.gpb.2018.10.002.
- 58F. Fouhy, C. Watkins, C. J. Hill, et al., “Perinatal Factors Affect the Gut Microbiota Up to Four Years After Birth,” Nature Communications 10, no. 1 (2019): 1517, https://doi.org/10.1038/s41467-019-09252-4.
- 59N. Tuikhar, S. Keisam, R. K. Labala, et al., “Comparative Analysis of the Gut Microbiota in Centenarians and Young Adults Shows a Common Signature Across Genotypically Non-Related Populations,” Mechanisms of Ageing and Development 179, (2019): 23–35, https://doi.org/10.1016/j.mad.2019.02.001.
- 60C. Xu, H. Zhu, and P. Qiu, “Aging Progression of Human Gut Microbiota,” BMC Microbiology 19, no. 1 (2019): 236, https://doi.org/10.1186/s12866-019-1616-2.
- 61R. I. Clark, A. Salazar, R. Yamada, et al., “Distinct Shifts in Microbiota Composition during Drosophila Aging Impair Intestinal Function and Drive Mortality,” Cell Reports 12, no. 10 (2015): 1656–1667, https://doi.org/10.1016/j.celrep.2015.08.004.
- 62N. Thevaranjan, A. Puchta, C. Schulz, et al., “Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction,” Cell Host and Microbe 21, no. 4 (2017): 455–466.e4, https://doi.org/10.1016/j.chom.2017.03.002.
- 63J. F. Colbert, J. M. Kirsch, C. L. Erzen, et al., “Aging-Associated Augmentation of Gut Microbiome Virulence Capability Drives Sepsis Severity,” MBio 14, no. 3 (2023): e0005223, https://doi.org/10.1128/mbio.00052-23.
- 64R. A. Fielding, A. R. Reeves, R. Jasuja, C. Liu, B. B. Barrett, and M. S. Lustgarten, “Muscle Strength Is Increased in Mice That Are Colonized with Microbiota From High-Functioning Older Adults,” Experimental Gerontology 127, (2019): 110722, https://doi.org/10.1016/j.exger.2019.110722.
- 65M. G. Valle Gottlieb, V. E. Closs, V. M. Junges, and C. H. A. Schwanke, “Impact of Human Aging and Modern Lifestyle on Gut Microbiota,” Critical Reviews in Food Science and Nutrition 58, no. 9 (2018): 1557–1564, https://doi.org/10.1080/10408398.2016.1269054.
- 66M. Kumar, P. Babaei, B. Ji, and J. Nielsen, “Human Gut Microbiota and Healthy Aging: Recent Developments and Future Prospective,” Nutrition and Healthy Aging 4, (2016): 3–16, https://doi.org/10.3233/NHA-150002.
- 67J. Zwielehner, K. Liszt, M. Handschur, C. Lassl, A. Lapin, and A. G. Haslberger, “Combined PCR-DGGE Fingerprinting and Quantitative-PCR Indicates Shifts in Fecal Population Sizes and Diversity of Bacteroides, Bifidobacteria and Clostridium Cluster IV in Institutionalized Elderly,” Experimental Gerontology 44, no. 6 (2009): 440–446, https://doi.org/10.1016/j.exger.2009.04.002.
- 68M. J. Alfa, D. Strang, P. S. Tappia, et al., “A Randomized Trial to Determine the Impact of a Digestion Resistant Starch Composition on the Gut Microbiome in Older and Mid-Age Adults,” Clinical Nutrition 37, no. 3 (2018): 797–807, https://doi.org/10.1016/j.clnu.2017.03.025.
- 69M. G. I. Langille, C. J. Meehan, J. E. Koenig, et al., “Microbial Shifts in the Aging Mouse Gut,” Microbiome 2, no. 1 (2014): 50, https://doi.org/10.1186/s40168-014-0050-9.
- 70X. You, U. C. Dadwal, M. E. Lenburg, M. A. Kacena, and J. F. Charles, “Murine Gut Microbiome Meta-analysis Reveals Alterations in Carbohydrate Metabolism in Response to Aging,” mSystems 7, no. 2 (2022): e0124821, https://doi.org/10.1128/msystems.01248-21.
- 71B. Sovran, F. Hugenholtz, M. Elderman, et al., “Age-Associated Impairment of the Mucus Barrier Function is Associated with Profound Changes in Microbiota and Immunity,” Scientific Reports 9, no. 1 (2019): 1437, https://doi.org/10.1038/s41598-018-35228-3.
- 72M. Elderman, B. Sovran, F. Hugenholtz, et al., “The Effect of Age on the Intestinal Mucus Thickness, Microbiota Composition and Immunity in Relation to Sex in Mice,” PLoS ONE 12, no. 9 (2017): e0184274, https://doi.org/10.1371/journal.pone.0184274.
- 73R. T. Mankowski, R. M. Thomas, D. B. Darden, et al., “Septic Stability? Gut Microbiota in Young Adult Mice Maintains Overall Stability After Sepsis Compared to Old Adult Mice,” Shock (Augusta, Ga.) 55, no. 4 (2021): 519–525, https://journals.lww.com/shockjournal/fulltext/2021/04000/septic_stability__gut_microbiota_in_young_adult.12.aspx.
- 74B. Flemer, N. Gaci, G. Borrel, et al., “Fecal Microbiota Variation Across the Lifespan of the Healthy Laboratory Rat,” Gut Microbes 8, no. 5 (2017): 428–439, https://doi.org/10.1080/19490976.2017.1334033.
- 75M. Bodogai, J. O'Connell, K. Kim, et al., “Commensal Bacteria Contribute to Insulin Resistance in Aging by Activating Innate B1a Cells,” Science Translational Medicine 10, no. 467 (2018): eaat4271, https://doi.org/10.1126/scitranslmed.aat4271.
- 76K.-A. Kim, J.-J. Jeong, S.-Y. Yoo, and D.-H. Kim, “Gut Microbiota Lipopolysaccharide Accelerates Inflamm-Aging in Mice,” BMC Microbiology 16, no. 1 (2016): 9, https://doi.org/10.1186/s12866-016-0625-7.
- 77C. Zhang, S. Li, L. Yang, et al., “Structural Modulation of Gut Microbiota in Life-Long Calorie-Restricted Mice,” Nature Communications 4, no. 1 (2013): 2163, https://doi.org/10.1038/ncomms3163.
- 78H. Mäkivuokko, L. Paulin, N. Rautonen, K. Tiihonen, and S. Tynkkynen, “The Effect of Age and Non-Steroidal Anti-Inflammatory Drugs on Human Intestinal Microbiota Composition,” British Journal of Nutrition 103, no. 2 (2010): 227–234, https://doi.org/10.1017/S0007114509991553.
- 79R. Vemuri, T. Shinde, R. Gundamaraju, et al., “Lactobacillus acidophilus DDS-1 Modulates the Gut Microbiota and Improves Metabolic Profiles in Aging Mice,” Nutrients 10, no. 9 (2018): 1255, https://doi.org/10.3390/nu10091255.
- 80E. Biagi, C. Franceschi, S. Rampelli, et al., “Gut Microbiota and Extreme Longevity,” Current Biology 26, no. 11 (2016): 1480–1485, https://doi.org/10.1016/j.cub.2016.04.016.
- 81S. Mueller, K. Saunier, C. Hanisch, et al., “Differences in Fecal Microbiota in Different European Study Populations in Relation to Age, Gender, and Country: A Cross-Sectional Study,” Applied and Environmental Microbiology 72, no. 2 (2006): 1027–1033, https://doi.org/10.1128/AEM.72.2.1027-1033.2006.
- 82M. Lopez-Siles, S. H. Duncan, L. J. Garcia-Gil, and M. Martinez-Medina, “Faecalibacterium prausnitzii: From Microbiology to Diagnostics and Prognostics,” The ISME Journal 11, no. 4 (2017): 841–852, https://doi.org/10.1038/ismej.2016.176.
- 83S. Yoshimoto, E. Mitsuyama, K. Yoshida, T. Odamaki, and J. Xiao, “Enriched Metabolites That Potentially Promote Age-Associated Diseases in Subjects with an Elderly-Type Gut Microbiota,” Gut Microbes 13, no. 1 (2021): 1–11, https://doi.org/10.1080/19490976.2020.1865705.
- 84M. N. Guentzel, “ Escherichia, Klebsiella, Enterobacter, Serratia, Citrobacter, and Proteus,” in Medical Microbiology, ed. S. Baron ( 4th ed. Galveston: University of Texas Medical Branch at Galveston, 1996).
- 85C.-C. Hung, C.-C. Chang, C.-W. Huang, R. Nouchi, and C.-H. Cheng, “Gut Microbiota in Patients with Alzheimer's Disease Spectrum: A Systematic Review and Meta-Analysis,” Aging (Albany NY) 14, no. 1 (2022): 477–496, 10.18632/aging.203826.
- 86S.-H. Park, K.-A. Kim, Y.-T. Ahn, J.-J. Jeong, C.-S. Huh, and D.-H. Kim, “Comparative Analysis of Gut Microbiota in Elderly People of Urbanized Towns and Longevity Villages,” BMC Microbiology 15, no. 1 (2015): 49, https://doi.org/10.1186/s12866-015-0386-8.
- 87M. Victoria, V.-D. B. Elena, G.-G. N. Amparo, et al., “Gut Microbiota Alterations in Critically Ill Older Patients: A Multicenter Study,” BMC Geriatrics 22, no. 1 (2022): 373, https://doi.org/10.1186/s12877-022-02981-0.
- 88T. Maioli, E. Borras-Nogues, L. Torres, et al., “Possible Benefits of Faecalibacterium prausnitzii for Obesity-Associated Gut Disorders,” Frontiers in Pharmacology 12, (2021): 740636, https://doi.org/10.3389/fphar.2021.740636.
- 89M. Duan, Y. Wang, Q. Zhang, R. Zou, M. Guo, and H. Zheng, “Characteristics of Gut Microbiota in People with Obesity,” PLoS ONE 16, no. 8 (2021): e0255446, https://doi.org/10.1371/journal.pone.0255446.
- 90V. F. Rodrigues, J. Elias-Oliveira, Í. S. Pereira, et al., “Akkermansia muciniphila and Gut Immune System: A Good Friendship That Attenuates Inflammatory Bowel Disease, Obesity, and Diabetes,” Frontiers in Immunology 13, (2022): 934695, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.934695.
- 91Q. Pan, Y.-Q. Li, K. Guo, et al., “Elderly Patients with Mild Cognitive Impairment Exhibit Altered Gut Microbiota Profiles,” Journal of Immunology Research 2021, (2021): 5578958, https://doi.org/10.1155/2021/5578958.
- 92K. E. Morrison, E. Jašarević, C. D. Howard, and T. L. Bale, “It's the Fiber, Not the Fat: Significant Effects of Dietary Challenge on the Gut Microbiome,” Microbiome 8, no. 1 (2020): 15, https://doi.org/10.1186/s40168-020-0791-6.
- 93A. P. M. van Soest, G. D. A. Hermes, A. A. M. Berendsen, et al., “Associations between Pro- and Anti-Inflammatory Gastro-Intestinal Microbiota, Diet, and Cognitive Functioning in Dutch Healthy Older Adults: The NU-AGE Study,” Nutrients 12, no. 11 (2020): 3471, https://doi.org/10.3390/nu12113471.
- 94L. Valentini, A. Pinto, I. Bourdel-Marchasson, et al., “Impact of Personalized Diet and Probiotic Supplementation on Inflammation, Nutritional Parameters and Intestinal Microbiota – The “RISTOMED Project”: Randomized Controlled Trial in Healthy Older People,” Clinical Nutrition 34, no. 4 (2015): 593–602, https://doi.org/10.1016/j.clnu.2014.09.023.
- 95T. S. Ghosh, M. Das, I. B. Jeffery, and P. W. O'Toole, “Adjusting for Age Improves Identification of Gut Microbiome Alterations in Multiple Diseases,” Elife 9, (2020): e50240, https://doi.org/10.7554/eLife.50240.
- 96D. Houghton, C. J. Stewart, C. Stamp, et al., “Impact of Age-Related Mitochondrial Dysfunction and Exercise on Intestinal Microbiota Composition,” The journals of Gerontology. Series A 73, no. 5 (2018): 571–578, https://doi.org/10.1093/gerona/glx197.
- 97C. Dong, J. Yu, Y. Yang, et al., “Berberine, a Potential Prebiotic to Indirectly Promote Akkermansia Growth Through Stimulating Gut Mucin Secretion,” Biomedicine and Pharmacotherapy 139, (2021): 111595, https://doi.org/10.1016/j.biopha.2021.111595.
- 98S. U. Furuse, T. Ohse, A. Jo-Watanabe, et al., “Galacto-Oligosaccharides Attenuate Renal Injury with Microbiota Modification,” Physiological Reports 2, no. 7 (2014): e12029, https://doi.org/10.14814/phy2.12029.
- 99J. Fernández, E. Ledesma, J. Monte, et al., “Traditional Processed Meat Products Re-designed Towards Inulin-Rich Functional Foods Reduce Polyps in Two Colorectal Cancer Animal Models,” Scientific Reports 9, no. 1 (2019): 14783, https://doi.org/10.1038/s41598-019-51437-w.
- 100V. T. Pham, C. Lacroix, C. P. Braegger, and C. Chassard, “Lactate-Utilizing Community Is Associated with Gut Microbiota Dysbiosis in Colicky Infants,” Scientific Reports 7, no. 1 (2017): 11176, https://doi.org/10.1038/s41598-017-11509-1.
- 101R. Grimaldi, G. R. Gibson, J. Vulevic, et al., “A Prebiotic Intervention Study in Children with Autism Spectrum Disorders (ASDs),” Microbiome 6, no. 1 (2018): 133, https://doi.org/10.1186/s40168-018-0523-3.
- 102S. P. Wang, L. A. Rubio, S. H. Duncan, et al., “Pivotal Roles for pH, Lactate, and Lactate-Utilizing Bacteria in the Stability of a Human Colonic Microbial Ecosystem,” mSystems 5, no. 5 (2020): e00645-e00720, https://doi.org/10.1128/msystems.00645-20.
- 103C. Lin, Z. Zeng, Y. Lin, et al., “Naringenin Suppresses Epithelial Ovarian Cancer by Inhibiting Proliferation and Modulating Gut Microbiota,” Phytomedicine 106, (2022): 154401, https://doi.org/10.1016/j.phymed.2022.154401.
- 104H. Xu, C. Cao, Y. Ren, et al., “Antitumor Effects of Fecal Microbiota Transplantation: Implications for Microbiome Modulation in Cancer Treatment,” Frontiers in immunology 13, (2022): 949490, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.949490.
- 105D. Chen, J. Wu, D. Jin, B. Wang, and H. Cao, “Fecal Microbiota Transplantation in Cancer Management: Current Status and Perspectives,” International Journal of Cancer 145, no. 8 (2019): 2021–2031, https://doi.org/10.1002/ijc.32003.
- 106J. Ren, H. Li, G. Zeng, B. Pang, Q. Wang, and J. Wei, “Gut Microbiome-Mediated Mechanisms in Aging-Related Diseases: Are Probiotics Ready for Prime Time?” Frontiers in Pharmacology 14, (2023): 1178596, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1178596.
- 107D. Spakowicz, A. Bibi, M. Muniak, N. F. Williams, R. Hoyd, and C. J. Presley, “The Aging Microbiome and Response to Immunotherapy: Considerations for the Treatment of Older Adults with Cancer,” Journal of Geriatric Oncology 12, no. 6 (2021): 985–989, https://doi.org/10.1016/j.jgo.2021.02.001.
- 108A. Biragyn and L. Ferrucci, “Gut Dysbiosis: A Potential Link Between Increased Cancer Risk in Ageing and Inflammaging,” The Lancet Oncology 19, no. 6 (2018): e295–e304, https://doi.org/10.1016/S1470-2045(18)30095-0.
- 109W. R. Brewster, W. C. Burkett, E. M. Ko, V. Bae-Jump, A. Nicole McCoy, and T. O. Keku, “An Evaluation of the Microbiota of the Upper Reproductive Tract of Women with and Without Epithelial Ovarian Cancer,” Gynecologic Oncology Reports 42, (2022): 101017, https://doi.org/10.1016/j.gore.2022.101017.
